Interestingly, the APOBEC3B mutation signature was detectable in colorectal and prostate cancers only when whole- genome, but not whole-exome, data were used, suggesting a tissue-specific bias against enrichment of mutations by APOBEC3B in coding regions. This evidence concerns the gene APOBEC3B and prostate carcinoma.